Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) Overview | 9 | 1 |
| Therapeutics Development | 10 | 4 |
| Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) Products under Development by Stage of Development | 10 | 1 |
| Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) Products under Development by Therapy Area | 11 | 1 |
| Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) Products under Development by Indication | 12 | 2 |
| Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) Pipeline Products Glance | 14 | 2 |
| Late Stage Products | 14 | 1 |
| Early Stage Products | 15 | 1 |
| Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) Products under Development by Companies | 16 | 5 |
| Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) Products under Development by Universities/Institutes | 21 | 2 |
| Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) Therapeutics Assessment | 23 | 7 |
| Assessment by Monotherapy/Combination Products | 23 | 1 |
| Assessment by Mechanism of Action | 24 | 2 |
| Assessment by Route of Administration | 26 | 2 |
| Assessment by Molecule Type | 28 | 2 |
| Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) Companies Involved in Therapeutics Development | 30 | 20 |
| Amgen Inc. | 30 | 1 |
| ArQule, Inc. | 31 | 1 |
| Astellas Pharma Inc. | 32 | 1 |
| AstraZeneca Plc | 33 | 1 |
| AVEO Pharmaceuticals, Inc. | 34 | 1 |
| Blueprint Medicines Corporation | 35 | 1 |
| Bristol-Myers Squibb Company | 36 | 1 |
| Daiichi Sankyo Company, Limited | 37 | 1 |
| Eddingpharm | 38 | 1 |
| Eisai Co., Ltd. | 39 | 2 |
| Eli Lilly and Company | 41 | 1 |
| Genosco | 42 | 1 |
| H3 Biomedicine Inc. | 43 | 1 |
| Ionis Pharmaceuticals, Inc. | 44 | 1 |
| Johnson &Johnson | 45 | 1 |
| NGM Biopharmaceuticals, Inc. | 46 | 1 |
| Novartis AG | 47 | 1 |
| Principia Biopharma Inc. | 48 | 1 |
| Vichem Chemie Research Ltd. | 49 | 1 |
| Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) Drug Profiles | 50 | 38 |
| ARQ-087 Drug Profile | 50 | 2 |
| ASP-5878 Drug Profile | 52 | 1 |
| AZ-709 Drug Profile | 53 | 1 |
| BLU-554 Drug Profile | 54 | 2 |
| BLU-9931 Drug Profile | 56 | 1 |
| BMS-986036 Drug Profile | 57 | 1 |
| EDP-317 Drug Profile | 58 | 1 |
| erdafitinib Drug Profile | 59 | 2 |
| FGF-401 Drug Profile | 61 | 1 |
| H-3B6527 Drug Profile | 62 | 1 |
| infigratinib Drug Profile | 63 | 2 |
| IONIS-463588 Drug Profile | 65 | 1 |
| lenvatinib mesylate Drug Profile | 66 | 11 |
| LQN-725 Drug Profile | 77 | 1 |
| LY-2874455 Drug Profile | 78 | 1 |
| Monoclonal Antibody to Antagonize FGFR4 for Cancer Drug Profile | 79 | 1 |
| NGM-282 Drug Profile | 80 | 2 |
| PRN-1371 Drug Profile | 82 | 1 |
| Recombinant Protein to Agonize FGFR for Type 2 Diabetes Drug Profile | 83 | 1 |
| Recombinant Proteins to Agonize FGFR for Metabolic Disorders Drug Profile | 84 | 1 |
| Small Molecule to Antagonize FGFR4 for Hepatocellular Carcinoma Drug Profile | 85 | 1 |
| Small Molecules to Antagonize Pan FGFR for Oncology Drug Profile | 86 | 1 |
| U3-1784 Drug Profile | 87 | 1 |
| Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) Dormant Projects | 88 | 1 |
| Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) Discontinued Products | 89 | 1 |
| Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) Featured News &Press Releases | 90 | 12 |
| Jul 04, 2016: Eisai Launches In-House Developed Novel Anticancer Agent Lenvima In Mexico | 90 | 1 |
| Jun 30, 2016: ArQule Presents Preliminary Clinical Data for ARQ 087 Demonstrating Evidence of Anticancer Activity in Intrahepatic Cholangiocarcinoma at the ESMO 18th World Congress on Gastrointestinal Cancer | 90 | 1 |
| Jun 23, 2016: ArQule to Present Preliminary Phase 1/2 Data for FGFR Inhibitor, ARQ 087, in Intrahepatic Cholangiocarcinoma at the ESMO 18th World Congress on Gastrointestinal Cancer | 91 | 1 |
| Jun 06, 2016: Principia Biopharma Announces Presentation of Initial Clinical Data on PRN1371 at 2016 American Society of Clinical Oncology Annual Meeting | 91 | 1 |
| May 31, 2016: City Of Hope researchers present data on BGJ398 at the American Society of Clinical Oncology s Annual Meeting | 92 | 1 |
| May 24, 2016: Eisai To Present on Lenvima at 52nd Annual Meeting of the American Society of Clinical Oncology | 92 | 1 |
| May 16, 2016: U.S. FDA Approves additional indication for Eisai anti cancer agent LENVIMA in Combination with Everolimus as Treatment for Advanced Renal Cell Carcinoma | 93 | 1 |
| Apr 20, 2016: Eisai Announces Non-Clinical Research Findings At Aacr 107Th Annual Meeting Regarding Combination Of Anticancer Agent Lenvatinib With Everolimus | 94 | 1 |
| Apr 12, 2016: Highly Anticipated New Treatment Option Now Available for Canadians with Select Type of Thyroid Cancer | 95 | 1 |
| Mar 09, 2016: Lenvima (lenvatinib) Now Available in Israel as Important New Treatment for People with Advanced Thyroid Cancer | 96 | 1 |
| Feb 25, 2016: Eisai Slams the New Cancer Drug Fund that Further Delays Patient Access to New Cancer Drug | 97 | 1 |
| Jan 18, 2016: U.S. FDA Accepts for Priority Review sNDA for Eisai S Anticancer Agent Lenvatinib Seeking Approval for Renal Cell Carcinoma | 98 | 1 |
| Jan 12, 2016: Eisai Submits New Application In Europe For In-House Developed Anticancer Agent Lenvatinib Seeking Approval For Indication Covering Renal Cell Carcinoma | 98 | 2 |
| Dec 16, 2015: Lenvima (lenvatinib) Now Reimbursed for Advanced Thyroid Cancer in Sweden | 100 | 1 |
| Dec 15, 2015: ArQule Announces Orphan Drug Designation in Cholangiocarcinoma and Clinical Update for ARQ 087 | 100 | 2 |
| Appendix | 102 | 2 |
| Methodology | 102 | 1 |
| Coverage | 102 | 1 |
| Secondary Research | 102 | 1 |
| Primary Research | 102 | 1 |
| Expert Panel Validation | 102 | 1 |
| Contact Us | 102 | 1 |
| Disclaimer | 103 | 1 |